2021•Journal of Pharmaceutical Research InternationalOpen access
Role of Hypouricemic Agents in Tumor Lysis Syndrome: A Meta-Analysis
Waleed Alshehri, Abdulrahman Aljohani, Reem Hasaballah Alhasani, Anood Alshammari, Jwael A. Alhamoud, Atheer M Alruwaili, Omniah Salem D. Altemani, Ali Bahabri, Hassan Alahmadi, Shaykhah Salman A. Alderaan, Afnan Almutairi, Marwan Naif Alsehli, Mohammed Almohammadi, Faisal A. Almaleki, Hamoud T. Alotaibi
Open full text 1 citations
Abstract
Objective and background: Tumor lysis syndrome (TLS) is a life-threatening emergency and demands emergency care of effective outcome with minimal or no side effects. The Hypouricemic agents, including Rasburicase, Allopurinol and Febuxostate used for the management of TLS. This study was designed to evaluate the Role of Hypouricemic agents by analyzing TLS development rate, control of uric acid, and Creatinine levels. Methods: An extensive electronic data search was conducted by using all leading scientific databases. Twenty-six studies were selected to conduct this study, as per the inclusion criteria. Results: The Odd ratio of TLS development rate was 4.06, 1.24, and 1.49 by Rusbricase, Allopurinol & Febuxostate administration respectively. 95% confidence interval was reported by selected studies against TLS development rate, Uric acid, and Creatinine levels by administrating Rusbricase, Allopurinol & Febuxostate. Conclusion: All Hypouricemic agents, including Rasburicase, Allopurinol and Febuxostate, are effective to manage Tumor lysis Syndrome. However, a suitable and most effective intervention dose needs to identify with better efficacy and minimal side effects both in Adults and Children.